首页> 外国专利> 170-linked breast and ovarian cancer susceptibility gene

170-linked breast and ovarian cancer susceptibility gene

机译:170连锁的乳腺癌和卵巢癌易感基因

摘要

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.
机译:本发明总体上涉及人类遗传学领域。具体地,本发明涉及用于分离和检测人乳腺癌和卵巢癌易感基因(BRCA1)的方法和材料,其一些突变等位基因引起对癌症特别是乳腺癌和卵巢癌的易感性。更具体地,本发明涉及BRCA1基因中的种系突变及其在诊断乳腺癌和卵巢癌易感性中的用途。本发明进一步涉及人乳腺癌和卵巢癌中BRCA1基因的体细胞突变及其在人乳腺癌和卵巢癌的诊断和预后中的用途。另外,本发明涉及其他人类癌症中BRCA1基因的体细胞突变及其在人类癌症的诊断和预后中的用途。本发明还涉及在BRCA1基因中具有突变的人类癌症的治疗,包括基因治疗,蛋白质替代疗法和蛋白质模拟物。本发明进一步涉及用于癌症治疗的药物的筛选。最后,本发明涉及针对突变的BRCA1基因的筛选,其对于诊断乳腺癌和卵巢癌的易感性是有用的。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号